🔗 Share this article

While America continues making sweeping changes to its vaccine recommendations, a particular individual has emerged unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has focused upon potential deaths following Covid vaccination in her brief position at the FDA.

Planned Overhauls to Childhood Immunization Program

Health officials had intended to unveil sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, it is understood – a major change that would put the US out of step with many the global community with no evidence for benefit. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is set to present at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this calendar year.

A New Direction at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for ending some childhood immunization guidelines in the US so as to align more like Denmark, a country with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – typically the domain of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no obvious track record in medication creation, oversight or leadership, which has been standard for past heads of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Past commissioners of CBER would “understand legal statutes and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the sort of resume that prior appointees who headed CBER have had.”

CDER has an immense workload at the FDA, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one need to be looked after,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a major management aspect to the job, which manages in excess of 5,000 staff members. “It’s a enormous leadership role, if you perform it correctly,” she concluded.

Official Statement and Controversial Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this assignment indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions stem from inaccurate premises”.

“Her experience aligns with the duties of her role,” the official stated, citing the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed expedited therapy clearance system that allegedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a clearer, if concerning, history, critics said. She published a study using unverified public submissions to estimate the rate of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed revising regulations for novel immunizations and ending “non-essential” immunizations, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly suggested barring adolescent males from getting COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her beliefs and reverse-engineers to retrofit the evidence in a highly misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|